Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

FDA approves Lilly’s Jardiance for heart failure 

By Brian Buntz | February 24, 2022

Lilly/BoehringerEli Lilly and Company (NYSE:LLY) has announced that the FDA has approved Jardiance (empagliflozin) 10 mg to lower the risk of cardiovascular death and hospitalization in adults with heart failure.

Lilly developed the drug, an SGLT2 inhibitor, in collaboration with Boehringer Ingelheim.

Jardiance is contraindicated in adults with type 1 diabetes, given its potential to elevate the risk of ketoacidosis in such patients.

It is also contraindicated in patients who are hypersensitive to empagliflozin or the excipients in Jardiance.

FDA first approved Jardiance as a treatment for type 2 diabetes in 2014.

In 2016, it won an indication for reducing the risk of cardiovascular death in adults with type 2 diabetes.

Lilly also notes that the drug is not recommended for improving glycemic control in adults with type 2 diabetes with an estimated glomerular filtration rate (eGFR) under 30 mL/min/1.73 m2.

The company notes that the treatment is suitable with an eGFR as low as 20 mL/min/1.73 m2.

To win the approval, Lilly and Boehringer Ingelheim submitted data from Phase 3 trials, including the landmark EMPEROR-Preserved trial. That data showed that the drug resulted in a statistically significant improvement in patients with heart failure regardless of ejection fraction.

“Today’s approval means these demonstrated benefits can now help to address a significant unmet need for the approximately 3 million adults in the U.S. with preserved ejection fraction, a form of heart failure that has very limited treatment options,” said Dr. Javed Butler, chairman, Department of Medicine at the University of Mississippi.

Jardiance generated almost $4 billion in sales in 2020.

LLY shares ticked up about 2% to $243.00.


Filed Under: Cardiovascular
Tagged With: Boehringer Ingelheim, Eli Lilly, empagliflozin, Jardiance
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Astellas Pharma in the Drug Discovery & Development Pharma 50
FDA places clinical hold on Astellas clinical trial focused on Pompe disease
Acer
Acer Therapeutics launches Phase 3 study for vascular Ehlers-Danlos syndrome
AstraZeneca
AstraZeneca’s Farxiga met primary endpoint in Phase 3 heart failure trial 
Janssen
Janssen reports positive clinical trial data for its Xarelto to treat PAD effects

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50